GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology ...
Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational ...
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback